MiR-618 inhibits anaplastic thyroid cancer by repressing XIAP in one ATC cell line

Qianpeng Cheng1, Xingguang Zhang1, Xiuping Xu1

  • 1Department of endocrinology, The Military General Hospital of Beijing PLA, 100700 Beijing, PR China.

Annales D'Endocrinologie
|August 23, 2014
PubMed

Insights

MicroRNA-618 (miR-618) targets X-linked inhibitor of apoptosis protein (XIAP), inhibiting anaplastic thyroid cancer (ATC) growth. Overexpressing miR-618 reduces XIAP, suppressing ATC cell proliferation and invasion.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • X-linked inhibitor of apoptosis protein (XIAP) promotes cancer progression and is upregulated in anaplastic thyroid cancer (ATC).
  • MicroRNAs (miRNAs) are key regulators of gene expression involved in cell proliferation, migration, and invasion.

Purpose of the Study:

  • To identify miRNAs targeting XIAP and investigate their therapeutic potential in ATC.
  • To explore the role of miR-618 in regulating XIAP expression and its impact on ATC cell behavior.

Main Methods:

  • Quantitative real-time PCR (qPCR) to assess XIAP and miR-618 expression levels.
  • Luciferase assay to confirm XIAP as a direct target of miR-618.
  • CCK-8 and Transwell assays to evaluate the effects of miR-618 overexpression on ATC cell growth, invasion, and migration.

Main Results:

  • XIAP mRNA was significantly upregulated in ATC cells (8305C) compared to normal thyroid cells (Nthy-ori 3-1).
  • miR-618 was significantly downregulated in ATC cells and directly targeted XIAP, repressing its expression at mRNA and protein levels.
  • Overexpression of miR-618 inhibited 8305C cell proliferation, invasion, and migration.

Conclusions:

  • miR-618 acts as a tumor suppressor in ATC by targeting XIAP.
  • miR-618 holds potential as a therapeutic agent for inhibiting anaplastic thyroid cancer growth and metastasis.